{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-018161","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.589296+00:00","generated_at":"2026-05-16T01:48:52.206539+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Allarity Therapeutics doses first patients in VA-funded Phase 2 trial of stenoparib + temozolomide for relapsed SCLC","bullets":["First patients dosed with stenoparib and temozolomide in Phase 2 trial for relapsed small cell lung cancer (SCLC).","Trial fully funded by U.S. Department of Veterans Affairs, enrolling at 11 VA medical centers nationwide.","Stenoparib is a dual PARP and WNT pathway inhibitor; prior PARP inhibitors limited by hematologic toxicity.","CEO cites fast enrollment and high unmet need; ~60-70% of SCLC patients present with extensive-stage disease.","Stenoparib crosses blood-brain barrier, relevant for SCLC brain metastases."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-018161","json":"https://secwatch.observer/filing/0001213900-26-018161.json","markdown":"https://secwatch.observer/filing/0001213900-26-018161.md","text":"https://secwatch.observer/filing/0001213900-26-018161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026018161/0001213900-26-018161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390026018161/ea0277546-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:48:52.206539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}